493-80-1

Usage

Originator

Calcistin,Galenus

Manufacturing Process

3 Methods of producing of N-(β-N-phenyl-N-benzylaminoethyl)pyrrolidine: 1. A mixture of 100 parts of N-p-chloroethyl-N-benzylaniline and 100 parts of freshly distilled pyrrolidine are heated to boiling under reflux cooling for about 10 h. Diluted aqueous caustic soda lye is added to the reaction mixture until it shows an alkaline reaction. The reaction product formed and unchanged pyrrolidine are extracted with ether. The extract thus obtained is a subjected to a distillation. After the ether has evaporated, there is produced N-(β-Nphenyl-N-benzylaminoethyl)pyrrolidine, which boils at from 198° to 205°C under 1 mm pressure. 2. 34 parts of N-β-chloroethylpyrrolidine hydrochloride are dissolved together with 110 parts of N-benzylaniline in 400 parts of alcohol, and the solution is heated to boiling under reflux cooling for 15 h, while adding 0.5 part of copper powder. After filtering off the copper powder and driving off the alcohol, dilute caustic soda solution is added until the solution shows an alkaline reaction, whereupon the oil separated is distilled in vacuum. After a forerun of excess N-benzylaniline, there passes over as a main fraction the N- (β-N-phenyl-N-benzylaminoethyl)pyrrolidine, which boils at between 198° and 205°C under 1 mm pressure (mercury gauge). 3. 34 parts of N-β-chloroethylpyrrolidine hydrochloride are added to a solution of 120 parts of aniline in 500 parts of alcohol and the mixture is heated to boiling under reflux cooling for 12 h. After rendering the mixture alkaline by adding caustic soda solution, the excess aniline is driven off with steam. The N-(β-N-phenylaminoethyl)pyrrolidine left is fractionated in vacuo (boiling point 160° to 165°C), 98 parts of histapyrrodine are dissolved in 250 parts of 10% aqueous caustic soda solution and admixed with 65 parts of bensylchloride while vigorously stirring at from 50° to 60°C. The temperature is raised to 80° to 90°C for 1 h and the product worked up as indicated in the preceding examples. There is obtained the N-(β-N-phenyl-N-benzylaminoethyl) pyrrolidine in a 95% yield. In practice it is usually used as hydrochloride.

Therapeutic Function

Antihistaminic

InChI:InChI=1/C19H24N2/c1-3-9-18(10-4-1)17-21(19-11-5-2-6-12-19)16-15-20-13-7-8-14-20/h1-6,9-12H,7-8,13-17H2

Upstream product

• 36716-44-6 N-[2-(pyrrolidin-1-yl)ethyl]aniline 
• 100-44-7 benzyl chloride 
• 123-75-1 pyrrolidine 
• 758640-21-0 N-Benzylaniline 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 

Relevant academic research and scientific papers

Flavin monooxygenase metabolism: Why medicinal chemists should matter

FMO enzymes (FMOs) play a key role in the processes of detoxification and/or bioactivation of specific pharmaceuticals and xenobiotics bearing nucleophilic centers. The N-oxide and S-oxide metabolites produced by FMOs are often active metabolites. The FMOs are more active than cytochromes in the brain and work in tandem with CYP3A4 in the liver. FMOs might reduce the risk of phospholipidosis of CAD-like drugs, although some FMOs metabolites seem to be neurotoxic and hepatotoxic. However, in silico methods for FMO metabolism prediction are not yet available. This paper reports, for the first time, a substrate-specificity and catalytic-activity model for FMO3, the most relevant isoform of the FMOs in humans. The application of this model to a series of compounds with unknown FMO metabolism is also reported. The model has also been very useful to design compounds with optimal clearance and in finding erroneous literature data, particularly cases in which substances have been reported to be FMO3 substrates when, in reality, the experimentally validated in silico model correctly predicts that they are not.